Factors affecting choice of hemostatic agent for the hemophilia patient with an inhibitor antibody.
Achieving adequate hemostasis in patients with hemophilia and high-titer inhibitor antibodies remains a challenge despite the development of plasma-derived and recombinant therapies to bypass the inhibitory effect. A group of hemophilia treaters met to examine the factors that influence physician choices among the very costly and cumbersome available therapies. Specific knowledge deficits in need of prospective research were identified with respect to the rational treatment of inhibitor patients.
Monahan
Paul E
PE
Department of Pediatrics, University of North Carolina at Chapel Hill, North Carolina, USA. Paul_Monahan@med.unc.edu
Aledort
Louis M
LM
D000906:Antibodies / Q000097:blood*; D000917:Antibody Formation; D001779:Blood Coagulation Factors / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D005169:Factor VIII / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D015942:Factor VIIa / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D006467:Hemophilia A / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use
D000906:Antibodies; D001779:Blood Coagulation Factors; D011994:Recombinant Proteins; C025667:prothrombin complex concentrates; D005169:Factor VIII; D015942:Factor VIIa